Psilocybin and MDMA paired with therapy show promise for depression and PTSD in trials, but regulatory approval, durability, and trial design remain unsettled.

Sources: [1][2]

Evidence standingEarly human
Key facts
Portal
Mind & Cognition
Stage
Late-stage trials, approval contested
Evidence
Early human
Reversible
Reversible
Reviewed
May 2026
Read time
7 min
Contents

Page status

Blinding is difficult · Durability and safety data incomplete

Key takeaways

  • Trials pair a psychedelic with structured psychotherapy, not a drug alone.
  • Results in depression and PTSD are promising but face blinding and durability questions.
  • Regulatory approval has been uneven, underscoring unsettled evidence.

The approach

Psychedelic-assisted therapy combines a supervised dose of a compound such as psilocybin or MDMA with preparatory and integration psychotherapy. Trials in treatment-resistant depression and PTSD have reported meaningful improvements for many participants.

The model treats the drug as a catalyst for therapy rather than a stand-alone medication, which complicates comparison with conventional drug trials.

Why it is still early

Blinding is hard when participants can tell whether they received a psychedelic, and expectancy may inflate effects. Durability, optimal dosing, and safety in broader populations are not fully established.

Regulators have not uniformly accepted the evidence — at least one high-profile application was rejected pending stronger data — which keeps the field in the early-human, not established-practice, column.

Open questions

  • How much of the benefit survives rigorous blinding?
  • How long do effects last, and for whom is it unsafe?

Watchlist

Signals that would move this entry along the evidence scale.

Blinding-robust trialsDurability dataRegulatory decisions

References

  1. MDMA-assisted therapy for PTSD (phase 3). Mitchell et al., Nature Medicine, 2021
    Phase 3 trial reporting benefit for severe PTSD.
  2. Psilocybin vs escitalopram for depression. Carhart-Harris et al., NEJM, 2021
    Head-to-head trial of psilocybin therapy in depression.

Cite this page

Future Human Atlas. “Psychedelic-Assisted Therapy.” Last reviewed May 2026. https://future-human-wiki.vercel.app/articles/psychedelic-therapy

Suggest an edit